Journal article

A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers

Aflah Roohullah, Adam Cooper, Anna J Lomax, Jennifer Aung, Alan Barge, Lilian Chow, Mark McHale, Jayesh Desai, James R Whittle, Ben Tran, Paul de Souza, Lisa G Horvath

INVESTIGATIONAL NEW DRUGS | SPRINGER | Published : 2018

Abstract

Background The MET tyrosine kinase and its ligand, hepatocyte growth factor (HGF) also known as scatter factor, are associated with tumourigenesis and metastasis by promotion of scattering, proliferation, angiogenesis, motility and invasion. ASLAN-002 is a potent inhibitor of MET as well as related kinases. A phase I dose escalation study was conducted to determine the safety and pharmacokinetics of ASLAN-002 in patients with advanced cancer. Methods Patients with advanced or metastatic solid tumours, who had progressed on standard therapy or for whom standard therapy was not known, were administered ASLAN-002 orally. The starting dose was 100 mg once daily (QD) with subsequent cohorts to re..

View full abstract